About Event
Don’t miss the only event helping to improve efficacy of traditional payloads, diversify mechanisms of action in toolkits of payloads and broader therapeutics applications of ADCs in cancer and beyond!
We are currently riding a wave of innovation following major successes from the lower potency Topo1 payloads used in Trodlevy and Enhertu. Drug developers are looking to expand their toolkit of payloads with optimized topo1 inhibitors, tubulin inhibitors and DNA damaging agents, and leveraging completely novel mechanisms of action, such as the NMT inhibitors, amanitin based toxins and oligonucleotide payloads.
This is your only opportunity to hear in-depth presentations from leading ADC developers focussed on physiochemical structural modifications and novel discoveries in the ADC payload field.